GHRP-6

What is GHRP-6?

GHRP-6 is a synthetic hexapeptide that signals the pituitary gland to release growth hormone. It belongs to a class called growth hormone secretagogues: small molecules and peptides that push the body's own growth hormone output rather than replacing it. GHRP-6 is one of the earliest growth hormone releasing peptides, developed during the foundational growth hormone secretagogue research of the 1980s.

Unlike growth hormone itself, GHRP-6 does not add hormone directly. It nudges the pituitary through a specific receptor. That receptor is shared with the body's natural hunger and growth-hormone signal, ghrelin, which is the reason its appetite effect stands out.

GHRP-6 is sold and studied as a research chemical. There are no large modern controlled trials establishing standardized therapeutic use in humans, so this page describes what the mechanism and the surrounding secretagogue literature report, not a protocol.

How does GHRP-6 work in the GH axis?

GHRP-6 binds the growth hormone secretagogue receptor, GHS-R1a, the same receptor activated by ghrelin, and this triggers a pulse of growth hormone from the pituitary.

The growth hormone axis has two main "go" signals. One is growth hormone releasing hormone (GHRH), which agents like CJC-1295 imitate. The other is the ghrelin pathway through GHS-R1a, which GHRP-6, GHRP-2, ipamorelin, and oral MK-677 all act on. Because the two pathways are separate, secretagogues that hit them are sometimes studied together, since a GHRH-side agent and a ghrelin-side agent can raise growth hormone through different doors.

GHRP-6 is described as producing a short growth hormone pulse rather than a steady rise. That differs from a long-acting GHRH analog such as CJC-1295, which produced sustained growth hormone and IGF-1 after dosing in healthy adults (Teichman et al., 2006).

Why is GHRP-6 known for strong appetite?

Appetite stimulation is GHRP-6's signature effect because it activates the ghrelin receptor, and ghrelin is the body's main hunger signal.

When GHRP-6 binds GHS-R1a, it mimics part of what ghrelin does, and hunger is often reported to rise sharply soon after dosing. In the peptide literature this appetite effect is described as stronger for GHRP-6 than for GHRP-2, and much stronger than for ipamorelin, which was engineered to avoid many off-target effects. Controlled human trials that quantify GHRP-6's appetite response are limited, so the strength of the effect is reported qualitatively rather than as a precise percentage.

For some research contexts the appetite response is the point of interest; for others it is an unwanted side effect. Either way, it is the clearest way GHRP-6 differs from the more selective secretagogues.

What dosing has GHRP-6 research reported?

There are no large, completed controlled human trials that establish a standardized therapeutic dose range for GHRP-6, so no responsible dose can be stated here, and any personal dose decision belongs with a qualified clinician.

Historically GHRP-6 appeared in small physiology and diagnostic studies of growth hormone release, not in the kind of long-term dose-ranging trials that define modern dosing labels. Because of that gap, the most reliable numbers in this space come from related secretagogues, not GHRP-6 itself. The table below summarizes what verified trials reported for neighboring agents, framed as research findings, not recommendations.

Two points from that table matter for anyone reading GHRP-6 dose claims online. First, the metabolic effects seen with a long-term oral ghrelin-pathway agent were real and measurable: fasting glucose rose and insulin sensitivity fell (Nass et al., 2008). Second, GHRP-6 sits in the same receptor family, so glucose-related caution is reasonable even though GHRP-6 lacks its own long-term human data.

How long does GHRP-6 last?

GHRP-6 is short acting: it produces a brief growth hormone pulse rather than a sustained increase.

This short duration is why GHRP-6 is described as a short-pulse agent rather than a steady, continuous one. It contrasts with the two long-duration options in the class. CJC-1295 produced sustained growth hormone and IGF-1 levels after dosing in healthy adults (Teichman et al., 2006), and oral MK-677 was active on a once-daily schedule in its randomized trial (Nass et al., 2008). Precise published half-life values for GHRP-6 in humans are not well established in the verifiable literature, so it is best described by its action, a short pulse, rather than a single citable number.

What side effects does the research describe?

The most reported effects are strong appetite, mild water retention, and, because GHRP-6 is less selective than ipamorelin, increases in cortisol and, to a smaller degree, prolactin.

Selectivity is the key contrast. Ipamorelin was developed specifically as a selective secretagogue that releases growth hormone without a significant rise in ACTH or cortisol, unlike earlier growth hormone releasing peptides such as GHRP-6 (Raun et al., 1998). That is the clearest documented safety-relevant difference between GHRP-6 and the newer, cleaner peptide.

Blood sugar deserves separate attention. Ghrelin-pathway agents can affect glucose handling: in a randomized trial of older adults, oral MK-677 raised fasting glucose and lowered insulin sensitivity (Nass et al., 2008). GHRP-6 has not been through the same long trial, but it acts on the same receptor family, so the finding is worth weighing.

Because human safety data specific to GHRP-6 is thin, side effect discussion here is framed as reported and mechanistic, not as a full safety profile.

GHRP-6 vs ipamorelin vs GHRP-2

All three are ghrelin-receptor secretagogues, but ipamorelin is the most selective, GHRP-6 drives the most appetite, and GHRP-2 sits between them.

Appetite and selectivity ratings are relative descriptors from the secretagogue literature. Only ipamorelin's selectivity is supported by a controlled study cited here (Raun et al., 1998).

The short version: none of these three has modern large-trial human efficacy data behind body-composition marketing claims. The documented differences are mechanism and selectivity. GHRP-6 and GHRP-2 are older peptides whose profiles are described mainly through early physiology work and mechanism, which is why "research suggests" is the correct framing, not efficacy promises.

If your interest is a GHRH-side plus ghrelin-side pairing, the more common modern pairing uses ipamorelin rather than GHRP-6, which is why the CJC-1295 and ipamorelin combination is discussed on its own page.